Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on ...

This biotech has candidates in late-stage clinical development.

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

GLP-1 giant Eli Lilly has once again taken to the medium of short film to deliver an important message about obesity. | GLP-1 ...

Abivax (ABVX) stock cools as CEO denies talks between Eli Lilly (LLY) and the French government over U.S.-based pharma's ...

The choice isn't that hard.

Eli Lilly and Co. has received the Federal Drug Administration’s breakthrough therapy designation for a drug in development ...

Novo Nordisk oral Wegovy records 3,071 prescriptions in four days. Shares jump 6.5% as Eli Lilly oral weight loss drug awaits ...

(Removes reference to GLP-1s in reference to Lilly Direct patients in paragraph 15,) By Maggie Fick and Michael Erman SAN ...

Eli Lilly And Co (NYSE:LLY) and Novo Nordisk (NYSE:NVO), are reportedly being sued in Texas by compounding pharmacy Strive ...

BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting ...

Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment ...